|
1
|
Eric KK, Blaise YL, Leopold KK, Niaore SB,
Innocent MK, Arnaud AY and Michel K: Madelung's deformity: A case
report and review of the literature. Pan Afr Med J. 23:1372016.
|
|
2
|
Davydov DM, Lobanov AV, Morozov SG,
Gribova IE and Murashev AN: Neurodevelopment and
phenotype-modulating functions of S100B protein: A pilot study.
Physiol Behav. 140:188–196. 2015. View Article : Google Scholar
|
|
3
|
Wang D, Liu Q, Xiao D, Guo T, Ma Y, Duan
K, Wang J, Lu X, Feng B and Weng J: Microparticle entrapment for
drug release from porous-surfaced bone implants. J Microencapsul.
32:443–449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haenecour P, Floss C, Jose J, Amari S,
Lodders K, Jadhav M, Wang A and Gyngard F: Coordinated analysis of
two graphite grains from the Co3.0 Lap 031117 meteorite: First
identification of a co nova graphite and a presolar iron sulfide
subgrain. Astrophys J. 825:882016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Winther-Sørensen M, Galsgaard KD, Santos
A, Trammell SAJ, Sulek K, Kuhre RE, Pedersen J, Andersen DB,
Hassing AS, Dall M, et al: Glucagon acutely regulates hepatic amino
acid catabolism and the effect may be disturbed by steatosis. Mol
Metab. 42:1010802020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Erdal R, Birsoy K and Unlu G: Amino acid
metabolism in liver mitochondria: From homeostasis to disease.
Metabolites. 15:4462025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fung TS, Ryu KW and Thompson CB: Arginine:
At the crossroads of nitrogen metabolism. EMBO J. 44:1275–1293.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eriksen PL, Vilstrup H, Rigbolt K, Suppli
MP, Sørensen M, Heebøll S, Veidal SS, Knop FK and Thomsen KL:
Non-alcoholic fatty liver disease alters expression of genes
governing hepatic nitrogen conversion. Liver Int. 39:2094–2101.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reece TB and Cleveland JC Jr: Noteworthy
literature in cardiac surgery 2015. Semin Cardiothorac Vasc Anesth.
20:34–39. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, He WS, Wang C, Yan YG, Ouyang ZH,
Xue JB, Li XL and Wang WJ: Application of vascularized fibular
graft for reconstruction and stabilization of multilevel cervical
tuberculosis: A case report. Medicine (Baltimore). 97:e93822018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lysaght J: The 'obesity paradox' in action
with cancer immunotherapy. Nat Rev Endocrinol. 15:132–133. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tang K, Zhang H, Deng J, Wang D, Liu S, Lu
S, Cui Q, Chen C, Liu J, Yang Z, et al: Ammonia detoxification
promotes CD8(+) T cell memory development by urea and citrulline
cycles. Nat Immunol. 24:162–173. 2023. View Article : Google Scholar
|
|
13
|
Haberle J, Boddaert N, Burlina A,
Chakrapani A, Dixon M, Huemer M, Karall D, Martinelli D, Crespo PS,
Santer R, et al: Suggested guidelines for the diagnosis and
management of urea cycle disorders. Orphanet J Rare Dis. 7:322012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morris SM Jr: Arginine metabolism
revisited. J Nutr. 146:2579S–2586S. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Makris G, Veit L, Rüfenacht V, Klassa S,
Zürcher N, Matsumoto S, Poms M and Häberle J: Expression and
function of the urea cycle in widely-used hepatic cellular models.
J Inherit Metab Dis. 47:1228–1238. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morris SM Jr: Regulation of enzymes of the
urea cycle and arginine metabolism. Annu Rev Nutr. 22:87–105. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Caldovic L, Ahn J, Jandricovic J, Balick
VM, Brayer M, Chansky PA, Dawson T, Edwards AC, Felsen SE, Ismat K,
et al: Datamining approaches for examining the low prevalence of
N-acetylglutamate synthase deficiency and understanding
transcriptional regulation of urea cycle genes. J Inherit Metab
Dis. 47:1175–1193. 2024. View Article : Google Scholar :
|
|
18
|
Heibel SK, Lopez GY, Panglao M, Sodha S,
Mariño-Ramírez L, Tuchman M and Caldovic L: Transcriptional
regulation of N-acetylglutamate synthase. PLoS One. 7:e295272012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brulport A, Vaiman D, Bou-Maroun E,
Chagnon MC and Corre LL: Hepatic transcriptome and DNA methylation
patterns following perinatal and chronic BPS exposure in male mice.
BMC Genomics. 21:8812020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ko S, Russell JO, Tian J, Gao C, Kobayashi
M, Feng R, Yuan X, Shao C, Ding H, Poddar M, et al: Hdac1 regulates
differentiation of bipotent liver progenitor cells during
regeneration via Sox9b and Cdk8. Gastroenterology. 156:187–202.e14.
2019. View Article : Google Scholar
|
|
21
|
Hernandez Altemir F, Hernandez Montero S
and Moros Pena M: Combitube SA through submental route. A technical
innovation. J Craniomaxillofac Surg. 31:257–259. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu H, Dong H, Robertson K and Liu C: DNA
methylation suppresses expression of the urea cycle enzyme
carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular
carcinoma. Am J Pathol. 178:652–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soria LR, Makris G, D'Alessio AM, De
Angelis A, Boffa I, Pravata VM, Rüfenacht V, Attanasio S, Nusco E,
Arena P, et al: O-GlcNAcylation enhances CPS1 catalytic efficiency
for ammonia and promotes ureagenesis. Nat Commun. 13:52122022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan T, Kumar S, Skinner ME, Victor-Joseph
R, Abuaita M, Keijer J, Zhang J, Kunkel TJ, Liu Y, Petrunak EM, et
al: Human SIRT5 variants with reduced stability and activity do not
cause neuropathology in mice. iScience. 27:1099912024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakagawa T, Lomb DJ, Haigis MC and
Guarente L: SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and
regulates the urea cycle. Cell. 137:560–570. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park J, Chen Y, Tishkoff DX, Peng C, Tan
M, Dai L, Xie Z, Zhang Y, Zwaans BM, Skinner ME, et al:
SIRT5-mediated lysine desuccinylation impacts diverse metabolic
pathways. Mol Cell. 50:919–930. 2013. View Article : Google Scholar
|
|
27
|
Wu J, Liu J, Lapenta K, Desrouleaux R, Li
MD and Yang X: Regulation of the urea cycle by CPS1 O-GlcNAcylation
in response to dietary restriction and aging. J Mol Cell Biol.
14:mjac0162022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takakusa H, Mohar I, Kavanagh TJ, Kelly
EJ, Kaspera R and Nelson SD: Protein tyrosine nitration of
mitochondrial carbamoyl phosphate synthetase 1 and its functional
consequences. Biochem Biophys Res Commun. 420:54–60. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bak S, Leon IR, Jensen ON and Hojlund K:
Tissue specific phosphorylation of mitochondrial proteins isolated
from rat liver, heart muscle and skeletal muscle. J Proteome Res.
12:4327–4339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
De Chiara F, Heeboll S, Marrone G,
Montoliu C, Hamilton-Dutoit S, Ferrandez A, Andreola F, Rombouts K,
Grønbæk H, Felipo V, et al: Urea cycle dysregulation in
non-alcoholic fatty liver disease. J Hepatol. 69:905–915. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gallego-Duran R, Ampuero J, Pastor-Ramirez
H, Álvarez-Amor L, Del Campo JA, Maya-Miles D, Montero-Vallejo R,
Cárdenas-García A, Pareja MJ, Gato-Zambrano S, et al: Liver injury
in non-alcoholic fatty liver disease is associated with urea cycle
enzyme dysregulation. Sci Rep. 12:34182022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miyamoto T, Lo PHY, Saichi N, Ueda K,
Hirata M, Tanikawa C and Matsuda K: Argininosuccinate synthase 1 is
an intrinsic Akt repressor transactivated by p53. Sci Adv.
3:e16032042017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lim LQJ, Adler L, Hajaj E, Soria LR, Perry
RB, Darzi N, Brody R, Furth N, Lichtenstein M, Bab-Dinitz E, et al:
ASS1 metabolically contributes to the nuclear and cytosolic
p53-mediated DNA damage response. Nat Metab. 6:1294–1309. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Boycott C, Beetch M, Lubecka-Gajewska K,
Ramsey BS, Torregrosa-Allen S, Elzey BD, Cox A, Lanman NA, de Conti
A, Li M, et al: AMPK-Dependent epigenetic regulation of metabolism
mediates the anti-cancer action of pterostilbene in hepatocellular
carcinoma. Mol Nutr Food Res. 69:e702172025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mun GI, Kim IS, Lee BH and Boo YC:
Endothelial argininosuccinate synthetase 1 regulates nitric oxide
production and monocyte adhesion under static and laminar shear
stress conditions. J Biol Chem. 286:2536–2542. 2011. View Article : Google Scholar
|
|
36
|
Sun N and Zhao X: Argininosuccinate
synthase 1, arginine deprivation therapy and cancer management.
Front Pharmacol. 13:9355532022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Renouf S, Buquet C, Fairand A, Benamar M
and Husson A: Changes in levels of argininosuccinate lyase mRNA
during induction by glucagon and cyclic AMP in cultured foetal-rat
hepatocytes. Biochem J. 291(Pt 2): 609–613. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Latasa MU, Carretero MV, Garcia-Trevijano
ER, Torres L, Mato JM and Avila MA: Identification of
argininosuccinate lyase as a hypoxia-responsive gene in rat
hepatocytes. J Hepatol. 33:709–715. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Husson A, Renouf S, Fairand A, Buquet C,
Benamar M and Vaillant R: Expression of argininosuccinate lyase
mRNA in foetal hepatocytes. Regulation by glucocorticoids and
insulin. Eur J Biochem. 192:677–681. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Okun JG, Conway S, Schmidt KV, Schumacher
J, Wang X, de Guia R, Zota A, Klement J, Seibert O, Peters A, et
al: Molecular regulation of urea cycle function by the liver
glucocorticoid receptor. Mol Metab. 4:732–740. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Majaw T and Sharma R: Arginase I
expression is upregulated by dietary restriction in the liver of
mice as a function of age. Mol Cell Biochem. 407:1–7. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu Y, Liu J, Wang J, Wang J, Lan P and
Wang T: USP25 stabilizes STAT6 to promote IL-4-induced macrophage
M2 polarization and fibrosis. Int J Biol Sci. 21:475–489. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pinos I, Yu J, Pilli N, Kane MA and
Amengual J: Functional characterization of interleukin 4 and
retinoic acid signaling crosstalk during alternative macrophage
activation. Biochim Biophys Acta Mol Cell Biol Lipids.
1868:1592912023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee B, Wu CY, Lin YW, Park SW and Wei LN:
Synergistic activation of Arg1 gene by retinoic acid and IL-4
involves chromatin remodeling for transcription initiation and
elongation coupling. Nucleic Acids Res. 44:7568–7579. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gray MJ, Poljakovic M, Kepka-Lenhart D and
Morris SM Jr: Induction of arginase I transcription by IL-4
requires a composite DNA response element for STAT6 and C/EBPbeta.
Gene. 353:98–106. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sheldon KE, Shandilya H, Kepka-Lenhart D,
Poljakovic M, Ghosh A and Morris SM Jr: Shaping the murine
macrophage phenotype: IL-4 and cyclic AMP synergistically activate
the arginase I promoter. J Immunol. 191:2290–2298. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huang L, He X, Peng W, He X, Xu B, Xu H,
Wang Y, Xu W, Chen W, Wang S, et al: Hyperuricemia induces liver
injury by upregulating HIF-1alpha and inhibiting arginine
biosynthesis pathway in mouse liver and human L02 hepatocytes.
Biochem Biophys Res Commun. 617(Pt 2): 55–61. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu M, Guo Y, Wang M, Luo X, Shen X, Li Z,
Wang L and Guo W: L-arginine homeostasis governs adult neural stem
cell activation by modulating energy metabolism in vivo. EMBO J.
42:e1126472023. View Article : Google Scholar
|
|
49
|
Wu G and Morris SM Jr: Arginine
metabolism: nitric oxide and beyond. Biochem J. 336(Pt 1): 1–17.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Farahani A, Farahani A, Kashfi K and
Ghasemi A: Inducible nitric oxide synthase (iNOS): More than an
inducible enzyme? Rethinking the classification of NOS isoforms.
Pharmacol Res. 216:1077812025. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Forstermann U and Sessa WC: Nitric oxide
synthases: Regulation and function. Eur Heart J. 33:829–837.
837a–837d. 2012. View Article : Google Scholar
|
|
52
|
Król M and Kepinska M: Human nitric oxide
synthase-its functions, polymorphisms and inhibitors in the context
of inflammation, diabetes and cardiovascular diseases. Int J Mol
Sci. 22:562020. View Article : Google Scholar
|
|
53
|
Rochette L, Lorin J, Zeller M, Guilland
JC, Lorgis L, Cottin Y and Vergely C: Nitric oxide synthase
inhibition and oxidative stress in cardiovascular diseases:
Possible therapeutic targets? Pharmacol Ther. 140:239–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Dong J, Li D, Kang L, Luo C and Wang J:
Insights into human eNOS, nNOS and iNOS structures and medicinal
indications from statistical analyses of their interactions with
bound compounds. Biophys Rep. 9:159–175. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Stuehr DJ: Mammalian nitric oxide
synthases. Biochim Biophys Acta. 1411:217–230. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Caldwell RW, Rodriguez PC, Toque HA,
Narayanan SP and Caldwell RB: Arginase: A multifaceted enzyme
important in health and disease. Physiol Rev. 98:641–665. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ren Y, Li Z, Li W, Fan X, Han F, Huang Y,
Yu Y, Qian L and Xiong Y: Arginase: Biological and therapeutic
implications in diabetes mellitus and its complications. Oxid Med
Cell Longev. 2022:24194122022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
West EE, Merle NS, Kaminski MM, Palacios
G, Kumar D, Wang L, Bibby JA, Overdahl K, Jarmusch AK, Freeley S,
et al: Loss of CD4(+) T cell-intrinsic arginase 1 accelerates Th1
response kinetics and reduces lung pathology during influenza
infection. Immunity. 56:2036–2053 e12. 2023. View Article : Google Scholar
|
|
59
|
Heuser SK, Li J, Pudewell S, LoBue A, Li Z
and Cortese-Krott MM: Biochemistry, pharmacology and in vivo
function of arginases. Pharmacol Rev. 77:1000152025. View Article : Google Scholar
|
|
60
|
Zhang M, Wu Z, Salas SS, Aguilar MM,
Trillos-Almanza MC, Buist-Homan M and Moshage H: Arginase 1
expression is increased during hepatic stellate cell activation and
facilitates collagen synthesis. J Cell Biochem. 124:808–817. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Paolini E, Longo M, Meroni M and
Dongiovanni P: Hepatic zonation in MASLD: Old question, new
challenge in the era of spatial omics. Int J Mol Sci. 26:107012025.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Haussinger D, Lamers WH and Moorman AF:
Hepatocyte heterogeneity in the metabolism of amino acids and
ammonia. Enzyme. 46:72–93. 1992.PubMed/NCBI
|
|
63
|
Cunningham RP and Porat-Shliom N: Liver
zonation-revisiting old questions with new technologies. Front
Physiol. 12:7329292021. View Article : Google Scholar
|
|
64
|
Lamers WH, Hilberts A, Furt E, Smith J,
Jonges GN, van Noorden CJ, Janzen JW, Charles R and Moorman AF:
Hepatic enzymic zonation: A reevaluation of the concept of the
liver acinus. Hepatology. 10:72–76. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yasaka TM, Kim CK, Meadows V and Monga SP:
Zonation, zonation, zonation: The real estate of the liver. Annu
Rev Pathol. 21:185–212. 2026. View Article : Google Scholar :
|
|
66
|
Brosnan ME and Brosnan JT: Hepatic
glutamate metabolism: A tale of 2 hepatocytes. Am J Clin Nutr.
90:857S–861S. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Frieg B, Görg B, Gohlke H and Häussinger
D: Glutamine synthetase as a central element in hepatic glutamine
and ammonia metabolism: Novel aspects. Biol Chem. 402:1063–1072.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Villar VH, Allega MF, Deshmukh R,
Ackermann T, Nakasone MA, Vande Voorde J, Drake TM, Oetjen J, Bloom
A, Nixon C, et al: Hepatic glutamine synthetase controls
N(5)-methylglutamine in homeostasis and cancer. Nat Chem Biol.
19:292–300. 2023. View Article : Google Scholar :
|
|
69
|
Gebhardt R and Matz-Soja M: Liver
zonation: Novel aspects of its regulation and its impact on
homeostasis. World J Gastroenterol. 20:8491–8504. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gebhardt R, Baldysiak-Figiel A, Krugel V,
Ueberham E and Gaunitz F: Hepatocellular expression of glutamine
synthetase: An indicator of morphogen actions as master regulators
of zonation in adult liver. Prog Histochem Cytochem. 41:201–266.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li W and He F: Infusion of kupffer cells
expanded in vitro ameliorated liver fibrosis in a murine model of
liver injury. Cell Transplant. 30:96368972110040902021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chen J, Deng X, Liu Y, Tan Q, Huang G, Che
Q, Guo J and Su Z: Kupffer cells in non-alcoholic fatty liver
disease: Friend or foe? Int J Biol Sci. 16:2367–2378. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Dixon LJ, Barnes M, Tang H, Pritchard MT
and Nagy LE: Kupffer cells in the liver. Compr Physiol. 3:785–797.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Rath M, Muller I, Kropf P, Closs EI and
Munder M: Metabolism via arginase or nitric oxide synthase: Two
competing arginine pathways in macrophages. Front Immunol.
5:5322014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Vilstrup H, Eriksen PL, Kjærgaard K,
Sørensen M, Thomsen KL and Ott P: Down the road towards hepatic
encephalopathy. Urea synthesis-the liver workhorse of nitrogen
metabolism. Metab Brain Dis. 40:492024. View Article : Google Scholar
|
|
76
|
Simpson KL, MacLeod EL, Kakajiwala A,
Gropman AL and Ah Mew N: Urea Cycle Disorders Overview.
GeneReviews® [Internet]. Adam MP, Feldman J, Mirzaa GM, Pagon RA,
Wallace SE and Amemiya A: University of Washington; Seattle, WA:
1993
|
|
77
|
Drews L, Zimmermann M, Westhoff P,
Brilhaus D, Poss RE, Bergmann L, Wiek C, Brenneisen P, Piekorz RP,
Mettler-Altmann T, et al: Ammonia inhibits energy metabolism in
astrocytes in a rapid and glutamate dehydrogenase 2-dependent
manner. Dis Model Mech. 13:dmm0471342020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Pogribny IP, Tryndyak VP, Bagnyukova TV,
Melnyk S, Montgomery B, Ross SA, Latendresse JR, Rusyn I and Beland
FA: Hepatic epigenetic phenotype predetermines individual
susceptibility to hepatic steatosis in mice fed a lipogenic
methyl-deficient diet. J Hepatol. 51:176–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Pirola CJ, Gianotti TF, Burgueño AL,
Rey-Funes M, Loidl CF, Mallardi P, Martino JS, Castaño GO and
Sookoian S: Epigenetic modification of liver mitochondrial DNA is
associated with histological severity of nonalcoholic fatty liver
disease. Gut. 62:1356–1363. 2013. View Article : Google Scholar
|
|
80
|
Thomsen KL, Eriksen PL, Kerbert AJ, De
Chiara F, Jalan R and Vilstrup H: Role of ammonia in NAFLD: An
unusual suspect. JHEP Rep. 5:1007802023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Niknahad H, Jamshidzadeh A, Heidari R,
Zarei M and Ommati MM: Ammonia-induced mitochondrial dysfunction
and energy metabolism disturbances in isolated brain and liver
mitochondria and the effect of taurine administration: Relevance to
hepatic encephalopathy treatment. Clin Exp Hepatol. 3:141–151.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Nisoli E and Carruba MO: Nitric oxide and
mitochondrial biogenesis. J Cell Sci. 119(Pt 14): 2855–2862. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Seth RK, Das S, Dattaroy D,
Chandrashekaran V, Alhasson F, Michelotti G, Nagarkatti M,
Nagarkatti P, Diehl AM, Bell PD, et al: TRPV4 activation of
endothelial nitric oxide synthase resists nonalcoholic fatty liver
disease by blocking CYP2E1-mediated redox toxicity. Free Radic Biol
Med. 102:260–273. 2017. View Article : Google Scholar
|
|
84
|
Garcia-Villafranca J, Guillen A and Castro
J: Involvement of nitric oxide/cyclic GMP signaling pathway in the
regulation of fatty acid metabolism in rat hepatocytes. Biochem
Pharmacol. 65:807–812. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pappas G, Wilkinson ML and Gow AJ: Nitric
oxide regulation of cellular metabolism: Adaptive tuning of
cellular energy. Nitric Oxide. 131:8–17. 2023. View Article : Google Scholar
|
|
86
|
Sprangers F, Sauerwein HP, Romijn JA, van
Woerkom GM and Meijer AJ: Nitric oxide inhibits glycogen synthesis
in isolated rat hepatocytes. Biochem J. 330(Pt 2): 1045–1049. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Cruz-Ojeda P, Navarro-Villarán E,
Fuertes-Agudo M, Mata A, López-Lluch G, Navas P, Cadenas S, Casado
M and Muntané J: Peroxynitrite is involved in the mitochondrial
dysfunction induced by Sorafenib in liver cancer cells. Free Radic
Biol Med. 229:251–263. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Babarasul MH, Bapir R, Rahman DHK,
Fakhralddin SS, Kakamad FH, Tahir SH, Ali RM, Abdalla BA, Mohammed
SH and Hussein DM: Synchronous ipsilateral papillary renal cell
carcinoma and urothelial carcinoma: A case report. Oncol Lett.
25:2212023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Riobo NA, Clementi E, Melani M, Boveris A,
Cadenas E, Moncada S and Poderoso JJ: Nitric oxide inhibits
mitochondrial NADH:ubiquinone reductase activity through
peroxynitrite formation. Biochem J. 359(Pt 1): 139–145. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Clementi E, Brown GC, Feelisch M and
Moncada S: Persistent inhibition of cell respiration by nitric
oxide: Crucial role of S-nitrosylation of mitochondrial complex I
and protective action of glutathione. Proc Natl Acad Sci USA.
95:7631–7636. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Navarro LA, Wree A, Povero D, Berk MP,
Eguchi A, Ghosh S, Papouchado BG, Erzurum SC and Feldstein AE:
Arginase 2 deficiency results in spontaneous steatohepatitis: A
novel link between innate immune activation and hepatic de novo
lipogenesis. J Hepatol. 62:412–420. 2015. View Article : Google Scholar
|
|
92
|
Sheldon RD, Padilla J, Jenkins NT,
Laughlin MH and Rector RS: Chronic NOS inhibition accelerates NAFLD
progression in an obese rat model. Am J Physiol Gastrointest Liver
Physiol. 308:G540–G549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Delgado TC, de Las Heras J and
Martínez-Chantar ML: Understanding gut-liver axis nitrogen
metabolism in Fatty liver disease. Front Endocrinol (Lausanne).
13:10581012022. View Article : Google Scholar :
|
|
94
|
Sunny NE, Parks EJ, Browning JD and
Burgess SC: Excessive hepatic mitochondrial TCA cycle and
gluconeogenesis in humans with nonalcoholic fatty liver disease.
Cell Metab. 14:804–810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Du K, Chitneni SK, Suzuki A, Wang Y, Henao
R, Hyun J, Premont RT, Naggie S, Moylan CA, Bashir MR, et al:
Increased glutaminolysis marks active scarring in nonalcoholic
steatohepatitis progression. Cell Mol Gastroenterol Hepatol.
10:1–21. 2020. View Article : Google Scholar :
|
|
96
|
Suppli MP, Bagger JI, Lund A, Demant M,
van Hall G, Strandberg C, Kønig MJ, Rigbolt K, Langhoff JL, Wewer
Albrechtsen NJ, et al: Glucagon resistance at the level of amino
acid turnover in obese subjects with hepatic steatosis. Diabetes.
69:1090–1099. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ducker GS and Rabinowitz JD: One-carbon
metabolism in health and disease. Cell Metab. 25:27–42. 2017.
View Article : Google Scholar
|
|
98
|
Radziejewska A, Muzsik A, Milagro FI,
Martínez JA and Chmurzynska A: One-carbon metabolism and
nonalcoholic fatty liver disease: The crosstalk between nutrients,
microbiota and genetics. Lifestyle Genom. 13:53–63. 2020.
View Article : Google Scholar
|
|
99
|
Pacana T, Cazanave S, Verdianelli A, Patel
V, Min HK, Mirshahi F, Quinlivan E and Sanyal AJ: Dysregulated
hepatic methionine metabolism drives homocysteine elevation in
diet-induced nonalcoholic fatty liver disease. PLoS One.
10:e01368222015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Sun C, Fan JG and Qiao L: Potential
epigenetic mechanism in non-alcoholic fatty liver disease. Int J
Mol Sci. 16:5161–5179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Trivedi P, Wang S and Friedman SL: The
power of plasticity-metabolic regulation of hepatic stellate cells.
Cell Metab. 33:242–257. 2021. View Article : Google Scholar
|
|
102
|
Yang F, Li H, Li Y, Hao Y, Wang C, Jia P,
Chen X, Ma S and Xiao Z: Crosstalk between hepatic stellate cells
and surrounding cells in hepatic fibrosis. Int Immunopharmacol.
99:1080512021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Han YP: Matrix metalloproteinases, the
pros and cons, in liver fibrosis. J Gastroenterol Hepatol. 21(Suppl
3): S88–S91. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Pudewell S, Lissy J, Nakhaeizadeh H, Taha
MS, Akbarzadeh M, Rezaei Adariani S, Nakhaei-Rad S, Li J, Kordes C,
Häussinger D, et al: Physical Interaction between Embryonic Stem
Cell-Expressed Ras (ERas) and Arginase-1 in quiescent hepatic
stellate cells. Cells. 11:5082022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Tsuchida T and Friedman SL: Mechanisms of
hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol.
14:397–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Povero D, Panera N, Eguchi A, Johnson CD,
Papouchado BG, de Araujo Horcel L, Pinatel EM, Alisi A, Nobili V
and Feldstein AE: Lipid-induced hepatocyte-derived extracellular
vesicles regulate hepatic stellate cell via microRNAs targeting
PPAR-gamma. Cell Mol Gastroenterol Hepatol. 1:646–663 e4. 2015.
View Article : Google Scholar
|
|
107
|
Higashi T, Friedman SL and Hoshida Y:
Hepatic stellate cells as key target in liver fibrosis. Adv Drug
Deliv Rev. 121:27–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Yin X, Peng J, Gu L, Liu Y, Li X, Wu J, Xu
B, Zhuge Y and Zhang F: Targeting glutamine metabolism in hepatic
stellate cells alleviates liver fibrosis. Cell Death Dis.
13:9552022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Chen Y, Choi SS, Michelotti GA, Chan IS,
Swiderska-Syn M, Karaca GF, Xie G, Moylan CA, Garibaldi F, Premont
R, et al: Hedgehog controls hepatic stellate cell fate by
regulating metabolism. Gastroenterology. 143:1319–1329 e11. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Nunez-Sanchez MA, Martinez-Sanchez MA,
Sierra-Cruz M, Lambertos A, Rico-Chazarra S, Oliva-Bolarín A,
Balaguer-Román A, Yuste JE, Martínez CM, Mika A, et al: Increased
hepatic putrescine levels as a new potential factor related to the
progression of metabolic dysfunction-associated steatotic liver
disease. J Pathol. 264:101–111. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Shi B, Wang W, Ye M, Liang M, Yu Z, Zhang
Y, Liu Z, Liang X, Ao J, Xu F, et al: Spermidine suppresses the
activation of hepatic stellate cells to cure liver fibrosis through
autophagy activator MAP1S. Liver Int. 43:1307–1319. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Huang R, Cui H, Yahya Ali Alshami MA, Fu
C, Jiang W, Cai M, Zhou S, Zhu X and Hu C: LOX-1 rewires glutamine
ammonia metabolism to drive liver fibrosis. Mol Metab.
96:1021322025. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Tang Z, Lin B, Li W, Li X, Liu F and Zhu
X: Y-box binding protein 1 promotes chromatin accessibility to
aggravate liver fibrosis. Cell Signal. 109:1107502023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Rojas A, Garcia-Lozano MR, Gil-Gomez A,
Romero-Gomez M and Ampuero J: Glutaminolysis-ammonia-urea cycle
axis, non-alcoholic fatty liver disease progression and development
of novel therapies. J Clin Transl Hepatol. 10:356–362. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Chen Z, Tang N, Wang X and Chen Y: The
activity of the carbamoyl phosphate synthase 1 promoter in human
liver-derived cells is dependent on hepatocyte nuclear factor
3-beta. J Cell Mol Med. 21:2036–2045. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Jalan R, De Chiara F, Balasubramaniyan V,
Andreola F, Khetan V, Malago M, Pinzani M, Mookerjee RP and
Rombouts K: Ammonia produces pathological changes in human hepatic
stellate cells and is a target for therapy of portal hypertension.
J Hepatol. 64:823–833. 2016. View Article : Google Scholar
|
|
117
|
Zhang H, Alsaleh G, Feltham J, Sun Y,
Napolitano G, Riffelmacher T, Charles P, Frau L, Hublitz P, Yu Z,
et al: Polyamines control eIF5A hypusination, TFEB translation and
autophagy to reverse B cell senescence. Mol Cell. 76:110–125 e9.
2019. View Article : Google Scholar
|
|
118
|
Okumura S, Teratani T, Fujimoto Y, Zhao X,
Tsuruyama T, Masano Y, Kasahara N, Iida T, Yagi S, Uemura T, et al:
Oral administration of polyamines ameliorates liver
ischemia/reperfusion injury and promotes liver regeneration in
rats. Liver Transpl. 22:1231–1244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Akinyele O and Wallace HM: Understanding
the polyamine and mTOR pathway interaction in breast cancer cell
growth. Med Sci (Basel). 10:512022.PubMed/NCBI
|
|
120
|
Iwakiri Y and Kim MY: Nitric oxide in
liver diseases. Trends Pharmacol Sci. 36:524–536. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Ozturk Akcora B, Vassilios Gabriel A,
Ortiz-Perez A and Bansal R: Pharmacological inhibition of STAT3
pathway ameliorates acute liver injury in vivo via inactivation of
inflammatory macrophages and hepatic stellate cells. FASEB Bioadv.
2:77–89. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Okina Y, Sato-Matsubara M, Kido Y,
Urushima H, Daikoku A, Kadono C, Nakagama Y, Nitahara Y, Hoang TH,
Thuy LTT, et al: Nitric oxide derived from cytoglobin-deficient
hepatic stellate cells causes suppression of cytochrome c oxidase
activity in hepatocytes. Antioxid Redox Signal. 38:463–479. 2023.
View Article : Google Scholar :
|
|
123
|
Bauer PM, Fukuto JM, Buga GM, Pegg AE and
Ignarro LJ: Nitric oxide inhibits ornithine decarboxylase by
S-nitrosylation. Biochem Biophys Res Commun. 262:355–358. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Ren XY, Li YN, Qi JS and Niu T:
Peroxynitrite-induced protein nitration contributes to liver
mitochondrial damage in diabetic rats. J Diabetes Complications.
22:357–364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Mueller BJ, Roberts MD, Mobley CB, Judd RL
and Kavazis AN: Nitric oxide in exercise physiology: Past and
present perspectives. Front Physiol. 15:15049782025. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Lira VA, Brown DL, Lira AK, Kavazis AN,
Soltow QA, Zeanah EH and Criswell DS: Nitric oxide and AMPK
cooperatively regulate PGC-1 in skeletal muscle cells. J Physiol.
588(Pt 18): 3551–3566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Rockey DC and Chung JJ: Inducible nitric
oxide synthase in rat hepatic lipocytes and the effect of nitric
oxide on lipocyte contractility. J Clin Invest. 95:1199–1206. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Palmieri EM, Gonzalez-Cotto M, Baseler WA,
Davies LC, Ghesquière B, Maio N, Rice CM, Rouault TA, Cassel T,
Higashi RM, et al: Nitric oxide orchestrates metabolic rewiring in
M1 macrophages by targeting aconitase 2 and pyruvate dehydrogenase.
Nat Commun. 11:6982020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Blas-Garcia A and Apostolova N: Novel
therapeutic approaches to liver fibrosis based on targeting
oxidative stress. Antioxidants (Basel). 12:15672023. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Gao H, Jin Z, Bandyopadhyay G, Cunha E,
Rocha K, Liu X, Zhao H, Zhang D, Jouihan H, Pourshahian S, et al:
MiR-690 treatment causes decreased fibrosis and steatosis and
restores specific Kupffer cell functions in NASH. Cell Metab.
34:978–990.e4. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Blériot C, Barreby E, Dunsmore G, Ballaire
R, Chakarov S, Ficht X, De Simone G, Andreata F, Fumagalli V, Guo
W, et al: A subset of Kupffer cells regulates metabolism through
the expression of CD36. Immunity. 54:2101–2116.e6. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Baffy G: Kupffer cells in non-alcoholic
fatty liver disease: The emerging view. J Hepatol. 51:212–223.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Ye D, Li FY, Lam KS, Li H, Jia W, Wang Y,
Man K, Lo CM, Li X and Xu A: Toll-like receptor-4 mediates
obesity-induced non-alcoholic steatohepatitis through activation of
X-box binding protein-1 in mice. Gut. 61:1058–1067. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Kazankov K, Jorgensen SMD, Thomsen KL,
Møller HJ, Vilstrup H, George J, Schuppan D and Grønbæk H: The role
of macrophages in nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis. Nat Rev Gastroenterol Hepatol. 16:145–159. 2019.
View Article : Google Scholar
|
|
135
|
Yin Y, Wang Q, Qi M, Zhang C, Li Z and
Zhang W: Ghrelin ameliorates nonalcoholic steatohepatitis induced
by chronic low-grade inflammation via blockade of Kupffer cell M1
polarization. J Cell Physiol. 236:5121–5133. 2021. View Article : Google Scholar
|
|
136
|
Zhang W and Lang R: Macrophage metabolism
in nonalcoholic fatty liver disease. Front Immunol. 14:12575962023.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Liu Y, Xu R, Gu H, Zhang E, Qu J, Cao W,
Huang X, Yan H, He J and Cai Z: Metabolic reprogramming in
macrophage responses. Biomark Res. 9:12021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Miura K, Kodama Y, Inokuchi S, Schnabl B,
Aoyama T, Ohnishi H, Olefsky JM, Brenner DA and Seki E: Toll-like
receptor 9 promotes steatohepatitis by induction of
interleukin-1beta in mice. Gastroenterology. 139:323–334.e7. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Nov O, Kohl A, Lewis EC, Bashan N, Dvir I,
Ben-Shlomo S, Fishman S, Wueest S, Konrad D and Rudich A:
Interleukin-1beta may mediate insulin resistance in liver-derived
cells in response to adipocyte inflammation. Endocrinology.
151:4247–4256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Zhang W, Kudo H, Kawai K, Fujisaka S, Usui
I, Sugiyama T, Tsukada K, Chen N and Takahara T: Tumor necrosis
factor-alpha accelerates apoptosis of steatotic hepatocytes from a
murine model of non-alcoholic fatty liver disease. Biochem Biophys
Res Commun. 391:1731–1736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Su L, Li N, Tang H, Lou Z, Chong X, Zhang
C, Su J and Dong X: Kupffer cell-derived TNF-α promotes hepatocytes
to produce CXCL1 and mobilize neutrophils in response to necrotic
cells. Cell Death Dis. 9:3232018. View Article : Google Scholar
|
|
142
|
Viola A, Munari F, Sanchez-Rodriguez R,
Scolaro T and Castegna A: The metabolic signature of macrophage
responses. Front Immunol. 10:14622019. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Scheja L and Kluwe J: Arginine and NASH-do
macrophages deliver the first hit? J Hepatol. 62:260–261. 2015.
View Article : Google Scholar
|
|
144
|
Tada Y, Kasai K, Makiuchi N, Igarashi N,
Kani K, Takano S, Honda H, Yanagibashi T, Watanabe Y,
Usui-Kawanishi F, et al: Roles of macrophages in advanced liver
fibrosis, identified using a newly established mouse model of
diet-induced non-alcoholic steatohepatitis. Int J Mol Sci.
23:132512022. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Yadav P, Ortega JG, Tamaki W, Chien C,
Chang KC, Biswas N, Pan S, Nilsson J, Yin X, Bhattacharyya A, et
al: Macrophage-fibroblast crosstalk drives Arg1-dependent lung
fibrosis via ornithine loading. J Clin Invest. 135:e1887342025.
View Article : Google Scholar
|
|
146
|
Clementi AH, Gaudy AM, van Rooijen N,
Pierce RH and Mooney RA: Loss of Kupffer cells in diet-induced
obesity is associated with increased hepatic steatosis, STAT3
signaling and further decreases in insulin signaling. Biochim
Biophys Acta. 1792:1062–1072. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Odegaard JI, Ricardo-Gonzalez RR, Red
Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L,
Ferrante AW and Chawla A: Alternative M2 activation of Kupffer
cells by PPARdelta ameliorates obesity-induced insulin resistance.
Cell Metab. 7:496–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Jentsch HFR, Dietrich M and Eick S:
Non-surgical periodontal therapy with adjunctive
amoxicillin/metronidazole or metronidazole when no aggregatibacter
actinomycetemcomitans is detected-A Randomized clinical trial.
Antibiotics (Basel). 9:6862020. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Liu C, Rajapakse AG, Riedo E, Fellay B,
Bernhard MC, Montani JP, Yang Z and Ming XF: Targeting arginase-II
protects mice from high-fat-diet-induced hepatic steatosis through
suppression of macrophage inflammation. Sci Rep. 6:204052016.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Lee JL, Wang YC, Hsu YA, Chen CS, Weng RC,
Lu YP, Chuang CY and Wan L: Galectin-12 modulates Kupffer cell
polarization to alter the progression of nonalcoholic fatty liver
disease. Glycobiology. 33:673–682. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Xiong X, Kuang H, Ansari S, Liu T, Gong J,
Wang S, Zhao XY, Ji Y, Li C, Guo L, et al: Landscape of
intercellular crosstalk in healthy and NASH liver revealed by
single-cell secretome gene analysis. Mol Cell. 75:644–660 e5. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Ramachandran P, Dobie R, Wilson-Kanamori
JR, Dora EF, Henderson BEP, Luu NT, Portman JR, Matchett KP, Brice
M, Marwick JA, et al: Resolving the fibrotic niche of human liver
cirrhosis at single-cell level. Nature. 575:512–518. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Zhang Y, Li J, Li H, Jiang J, Guo C, Zhou
C, Zhou Z and Ming Y: Single-cell RNA sequencing to dissect the
immunological network of liver fibrosis in Schistosoma
japonicum-infected mice. Front Immunol. 13:9808722022. View Article : Google Scholar
|
|
154
|
Liu K, Zhao E, Ilyas G, Lalazar G, Lin Y,
Haseeb M, Tanaka KE and Czaja MJ: Impaired macrophage autophagy
increases the immune response in obese mice by promoting
proinflammatory macrophage polarization. Autophagy. 11:271–284.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Pelletier K, Cote G, Madsen K, Chen S, Kim
SJ, Chan CT, Mattsson J, Pasic I and Kitchlu A: Chronic kidney
disease, survival and graft-versus-host-disease-free/relapse-free
survival in recipients of allogeneic hematopoietic stem cell
transplant. Clin Kidney J. 15:1583–1592. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Boga S, Alkim H, Koksal AR, Bayram M,
Ozguven MB, Ergun M, Neijmann ST, Ozgon G and Alkim C: Increased
plasma levels of asymmetric dimethylarginine in nonalcoholic fatty
liver disease: Relation with insulin resistance, inflammation and
liver histology. J Investig Med. 63:871–877. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Yang Y, Huang Z, Yang Z, Qi Y, Shi H, Zhou
Y, Wang F and Yang M: Serum metabolomic profiling reveals an
increase in homocitrulline in Chinese patients with nonalcoholic
fatty liver disease: A retrospective study. PeerJ. 9:e113462021.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Kalhan SC, Guo L, Edmison J, Dasarathy S,
McCullough AJ, Hanson RW and Milburn M: Plasma metabolomic profile
in nonalcoholic fatty liver disease. Metabolism. 60:404–413. 2011.
View Article : Google Scholar
|
|
159
|
Kim SK, Joe Y, Zheng M, Kim HJ, Yu JK, Cho
GJ, Chang KC, Kim HK, Han J, Ryter SW and Chung HT: Resveratrol
induces hepatic mitochondrial biogenesis through the sequential
activation of nitric oxide and carbon monoxide production. Antioxid
Redox Signal. 20:2589–2605. 2014. View Article : Google Scholar
|
|
160
|
Dai Z, Wu Z, Yang Y, Wang J, Satterfield
MC, Meininger CJ, Bazer FW and Wu G: Nitric oxide and energy
metabolism in mammals. Biofactors. 39:383–391. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Kingery JR, Hamid T, Lewis RK, Ismahil MA,
Bansal SS, Rokosh G, Townes TM, Ildstad ST, Jones SP and Prabhu SD:
Leukocyte iNOS is required for inflammation and pathological
remodeling in ischemic heart failure. Basic Res Cardiol.
112:192017. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Jia L, Wang Y, Jin C, Ma Y, Wang Y, Song
L, Shen J, Xie Y and Xiang M: Macrophage heme oxygenase-1 modulates
peroxynitrite-mediated vascular injury and exacerbates abdominal
aortic aneurysm development. Am J Physiol Cell Physiol.
328:C1808–C1821. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Butterworth RF and Canbay A:
Hepatoprotection by L-ornithine L-aspartate in non-alcoholic fatty
liver disease. Dig Dis. 37:63–68. 2019. View Article : Google Scholar :
|
|
164
|
Jegatheesan P, Beutheu S, Ventura G,
Nubret E, Sarfati G, Bergheim I and De Bandt JP: Citrulline and
nonessential amino acids prevent fructose-induced nonalcoholic
fatty liver disease in rats. J Nutr. 145:2273–2279. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Steixner-Kumar AA, Santacruz D, Geiger T,
Rust W, Böttner D, Krenkel O, Bahrami E, Okafo G, Barth TFE, Haenle
M, et al: Single-cell landscape of peripheral immune cells in
MASLD/MASH. Hepatol Commun. 9:e06432025. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Sugiyama Y, Shimura M, Ogawa-Tominaga M,
Ebihara T, Kinouchi Y, Isozaki K, Matsuhashi T, Tajika M, Fushimi
T, Ichimoto K, et al: Therapeutic effect of N-carbamylglutamate in
CPS1 deficiency. Mol Genet Metab Rep. 24:1006222020.PubMed/NCBI
|
|
167
|
Conte C and Muscaritoli M: Editorial:
Muscle mass and function in COVID-19. Front Nutr. 9:10127422022.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Naing A, Papadopoulos KP, Pishvaian MJ,
Rahma O, Hanna GJ, Garralda E, Saavedra O, Gogov S, Kallender H,
Cheng L, et al: First-in-human phase 1 study of the arginase
inhibitor INCB001158 alone or combined with pembrolizumab in
patients with advanced or metastatic solid tumours. BMJ Oncol.
3:e0002492024. View Article : Google Scholar
|
|
169
|
Fenwick N, Weston R, Wheatley K, Hodgson
J, Marshall L, Elliott M, Makin G, Ng A, Brennan B, Lowis S, et al:
PARC: A phase I/II study evaluating the safety and activity of
pegylated recombinant human arginase BCT-100 in relapsed/refractory
cancers of children and young adults. Front Oncol. 14:12965762024.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Russo RS, Gasperini S, Bubb G, Neuman L,
Sloan LS, Diaz GA and Enns GM; PEACE Investigators: Efficacy and
safety of pegzilarginase in arginase 1 deficiency (PEACE): A phase
3, randomized, double-blind, placebo-controlled, multi-centre
trial. EClinicalMedicine. 68:1024052024. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Lian TY, Jiang X and Jing ZC: Riociguat: A
soluble guanylate cyclase stimulator for the treatment of pulmonary
hypertension. Drug Des Devel Ther. 11:1195–1207. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Trujillo ME, Ayalasomayajula S, Blaustein
RO and Gheyas F: Vericiguat, a novel sGC stimulator: Mechanism of
action, clinical and translational science. Clin Transl Sci.
16:2458–2466. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Hanrahan JP, Seferovic JP, Wakefield JD,
Wilson PJ, Chickering JG, Jung J, Carlson KE, Zimmer DP, Frelinger
AL III, Michelson AD, et al: An exploratory, randomised,
placebo-controlled, 14 day trial of the soluble guanylate cyclase
stimulator praliciguat in participants with type 2 diabetes and
hypertension. Diabetologia. 63:733–743. 2020. View Article : Google Scholar :
|
|
174
|
Schwartzkopf CD, Hadcock JR, Liu G,
Germano P, Roux J, Shea CM, Buys ES and Jones JE: Beneficial
metabolic effects of praliciguat, a soluble guanylate cyclase
stimulator, in a mouse diet-induced obesity model. Front Pharmacol.
13:8520802022. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Hingorany S and Frishman WH: Soluble
guanylate cyclase activation with cinaciguat: A new approach to the
treatment of decompensated heart failure. Cardiol Rev. 19:23–29.
2011. View Article : Google Scholar
|
|
176
|
Gawrys O, Kala P, Sadowski J, Melenovsky
V, Sandner P and Cervenka L: Soluble guanylyl cyclase stimulators
and activators: Promising drugs for the treatment of hypertension?
Eur J Pharmacol. 987:1771752025. View Article : Google Scholar
|
|
177
|
Sawabe T, Chiba T, Kobayashi A, Nagasaka
K, Aihara K and Takaya A: A novel soluble guanylate cyclase
activator with reduced risk of hypotension by short-acting
vasodilation. Pharmacol Res Perspect. 7:e004632019. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Bhogal S, Khraisha O, Al Madani M, Treece
J, Baumrucker SJ and Paul TK: Sildenafil for pulmonary arterial
hypertension. Am J Ther. 26:e520–e526. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Rosenzweig EB: Tadalafil for the treatment
of pulmonary arterial hypertension. Expert Opin Pharmacother.
11:127–132. 2010. View Article : Google Scholar
|
